VitriVax, a Boulder, CO-based formulation technology company, received $5M two-year grant from Bill & Melinda Gates Foundation.
The grant will allow the company to develop further its proprietary single shot, thermostabilization vaccine technology (ALTA™) and begin the development of pilot-scale manufacturing capacity.
Led by CEO Romulo Colindres, VitriVax has engineered its proprietary atomic layering thermostable antigen and adjuvant (ALTA™) technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response of vaccines. ALTA™ can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses and additional booster doses in a single-shot administration. These technologies may also facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection.
FinSMEs
06/12/2023